IPO

Hawaiian beverage company Waiākea rolls out the world's first carbon-negative algae ink on its bottles, an open-source move to transform the industry.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.

With legendary geologist Doug Kirwin and Latin America expert Carlos Velásquez on board, Terra Rossa is set to unlock its high-grade Vetas gold project.

Empire Petroleum expands its capital raise and extends the deadline, backed by its largest shareholder in a significant vote of confidence for its growth plans.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

Legal tech firm DISCO reports strong growth fueled by a 600% surge in AI revenue, launching agentic AI and a disruptive new all-in-one pricing model.

In its first report as a public company, Medline posts $28.4B in annual sales but faces declining net income from tariffs and IPO costs.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

While many cannabis firms struggle, Greenway Greenhouse reports a 40% revenue jump, expanding margins, and its fifth straight quarter of positive EBITDA.

U.S. Energy Corp. unveils an ambitious plan to merge helium, oil, and carbon capture, but can this small-cap company deliver on its big promises?

Canaan deepens its US energy footprint by acquiring Cipher's Texas mining assets, making Cipher a major shareholder and signaling a broader industry shift to AI.

Shipping giant Matson posts strong Q4 results, buoyed by e-commerce and a stable US-China trade deal, and charts a course for growth with a $425M investment.

Navitas Semiconductor accepts short-term losses for a future in AI data centers and energy, signaling a major shift in the power electronics landscape.

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

The Raine Group hires Credit Suisse veteran Anthony Kontoleon, signaling a major push to dominate TMT advisory ahead of an anticipated tech boom.

Medtronic's diabetes arm hits the road for its IPO, seeking to raise up to $784M in a major test of investor appetite for specialized medtech firms.

Intellia Therapeutics prepares for a critical March, where it will outline its gene editing future to investors amid safety questions and market pressures.

With a promise of cellular renewal via exosomes, (plated) Skin Science is leading a biotech revolution. But can it navigate the hype and regulatory hurdles?

Leaving the volatile crypto world behind, Cipher Digital is raising billions to build massive data centers for tech giants like AWS and Google.